RU2527157C2 - Аттенуированный рекомбинантный парвовирус, пригодный для защиты собак от инфицирования парвовирусом - Google Patents
Аттенуированный рекомбинантный парвовирус, пригодный для защиты собак от инфицирования парвовирусом Download PDFInfo
- Publication number
- RU2527157C2 RU2527157C2 RU2012142309/10A RU2012142309A RU2527157C2 RU 2527157 C2 RU2527157 C2 RU 2527157C2 RU 2012142309/10 A RU2012142309/10 A RU 2012142309/10A RU 2012142309 A RU2012142309 A RU 2012142309A RU 2527157 C2 RU2527157 C2 RU 2527157C2
- Authority
- RU
- Russia
- Prior art keywords
- parvovirus
- attenuated
- recombinant
- capsid protein
- type
- Prior art date
Links
- 241000125945 Protoparvovirus Species 0.000 title claims abstract description 64
- 230000002238 attenuated effect Effects 0.000 title claims abstract description 27
- 208000008071 Parvoviridae Infections Diseases 0.000 title claims abstract description 8
- 206010057343 Parvovirus infection Diseases 0.000 title claims abstract description 8
- 241000700605 Viruses Species 0.000 claims abstract description 53
- 229960005486 vaccine Drugs 0.000 claims abstract description 32
- 108090000565 Capsid Proteins Proteins 0.000 claims abstract description 29
- 108020004414 DNA Proteins 0.000 claims abstract description 28
- 102100023321 Ceruloplasmin Human genes 0.000 claims abstract description 27
- 108091028043 Nucleic acid sequence Proteins 0.000 claims abstract description 7
- 241000701931 Canine parvovirus Species 0.000 claims description 39
- 239000012634 fragment Substances 0.000 claims description 34
- 241000282472 Canis lupus familiaris Species 0.000 claims description 25
- 208000015181 infectious disease Diseases 0.000 claims description 12
- 238000004113 cell culture Methods 0.000 claims description 7
- 238000001890 transfection Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 238000005215 recombination Methods 0.000 claims description 4
- 230000006798 recombination Effects 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000002068 genetic effect Effects 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 241001032492 Canine parvovirus 2 Species 0.000 claims 1
- 230000036039 immunity Effects 0.000 abstract description 5
- 229960004854 viral vaccine Drugs 0.000 abstract description 3
- 230000001681 protective effect Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
- 210000000234 capsid Anatomy 0.000 description 17
- 241000282326 Felis catus Species 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 9
- 239000013612 plasmid Substances 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 238000001712 DNA sequencing Methods 0.000 description 4
- 241000282887 Suidae Species 0.000 description 4
- 108020005202 Viral DNA Proteins 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 241000282465 Canis Species 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 208000005093 cerebellar hypoplasia Diseases 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000701915 Feline panleukopenia virus Species 0.000 description 2
- 239000012097 Lipofectamine 2000 Substances 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003754 fetus Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 208000025906 Aleutian Mink Disease Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000450599 DNA viruses Species 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000002613 Feline Panleukopenia Diseases 0.000 description 1
- 241000282324 Felis Species 0.000 description 1
- 208000001951 Fetal Death Diseases 0.000 description 1
- 206010055690 Foetal death Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000702625 Mink enteritis virus Species 0.000 description 1
- 241000428199 Mustelinae Species 0.000 description 1
- 208000021908 Myocardial disease Diseases 0.000 description 1
- 241000772415 Neovison vison Species 0.000 description 1
- 108091081548 Palindromic sequence Proteins 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 241000282335 Procyon Species 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 231100000479 fetal death Toxicity 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 230000006801 homologous recombination Effects 0.000 description 1
- 238000002744 homologous recombination Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 229940124590 live attenuated vaccine Drugs 0.000 description 1
- 229940023012 live-attenuated vaccine Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 208000018555 lymphatic system disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 244000062645 predators Species 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 208000017443 reproductive system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000002254 stillbirth Diseases 0.000 description 1
- 231100000537 stillbirth Toxicity 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/23—Parvoviridae, e.g. feline panleukopenia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14361—Methods of inactivation or attenuation
- C12N2750/14362—Methods of inactivation or attenuation by genetic engineering
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31103210P | 2010-03-05 | 2010-03-05 | |
| US61/311,032 | 2010-03-05 | ||
| EP10155646 | 2010-03-05 | ||
| EP10155646.2 | 2010-03-05 | ||
| PCT/EP2011/053164 WO2011107534A1 (en) | 2010-03-05 | 2011-03-03 | Recombinant attenuated parvovirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2012142309A RU2012142309A (ru) | 2014-04-10 |
| RU2527157C2 true RU2527157C2 (ru) | 2014-08-27 |
Family
ID=42562704
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012142309/10A RU2527157C2 (ru) | 2010-03-05 | 2011-03-03 | Аттенуированный рекомбинантный парвовирус, пригодный для защиты собак от инфицирования парвовирусом |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US9234182B2 (enExample) |
| EP (1) | EP2542260B1 (enExample) |
| JP (3) | JP6200155B2 (enExample) |
| CN (1) | CN102791288B (enExample) |
| AU (1) | AU2011222910B2 (enExample) |
| CA (1) | CA2790653C (enExample) |
| DK (1) | DK2542260T3 (enExample) |
| ES (1) | ES2566033T3 (enExample) |
| RU (1) | RU2527157C2 (enExample) |
| WO (1) | WO2011107534A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011107534A1 (en) * | 2010-03-05 | 2011-09-09 | Intervet International B.V. | Recombinant attenuated parvovirus |
| US9314519B2 (en) | 2012-08-21 | 2016-04-19 | Intervet Inc. | Liquid stable virus vaccines |
| US20140234354A1 (en) * | 2013-02-15 | 2014-08-21 | Boehringer Ingelheim Vetmedica, Inc. | Porcine parvovirus 5b, methods of use and vaccine |
| AR097762A1 (es) | 2013-09-27 | 2016-04-13 | Intervet Int Bv | Formulaciones secas de vacunas que son estables a temperatura ambiente |
| CN105263953B (zh) * | 2014-01-15 | 2020-01-07 | 勃林格殷格翰动物保健美国有限公司 | 猪细小病毒5a、使用方法及疫苗 |
| US10398773B2 (en) | 2014-04-17 | 2019-09-03 | Intervet Inc. | Porcine parvovirus |
| UA130511C2 (uk) | 2016-11-03 | 2026-03-11 | Бьорінгер Інгельхайм Ветмедіка Гмбх | Вакцина проти свинячого парвовірусу й вірусу свинячого репродуктивного й респіраторного синдрому та спосіб її одержання |
| EP4570264A3 (en) | 2016-11-03 | 2026-01-21 | Boehringer Ingelheim Vetmedica GmbH | Vaccine against porcine parvovirus |
| MX2023005182A (es) | 2020-11-04 | 2023-05-15 | Intervet Int Bv | Parvovirus canino. |
| CN114957406B (zh) * | 2022-05-26 | 2024-02-02 | 吉林大学 | 一种犬细小病毒的三价抗原和三价病毒样颗粒以及应用 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008157236A1 (en) * | 2007-06-14 | 2008-12-24 | The Board Of Regents For Oklahoma State University | Vaccines containing canine parvovirus genetic variants |
| RU2008102930A (ru) * | 2005-07-28 | 2009-07-27 | Пфайзер Продактс Инк. (Us) | Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8502399D0 (en) * | 1985-01-31 | 1985-03-06 | Akzo Nv | Canine parvovirus vaccines |
| EP1135468B1 (en) * | 1998-11-10 | 2010-01-06 | University Of North Carolina At Chapel Hill | Virus vectors and methods of making and administering the same |
| WO2011107534A1 (en) * | 2010-03-05 | 2011-09-09 | Intervet International B.V. | Recombinant attenuated parvovirus |
-
2011
- 2011-03-03 WO PCT/EP2011/053164 patent/WO2011107534A1/en not_active Ceased
- 2011-03-03 DK DK11706253.9T patent/DK2542260T3/en active
- 2011-03-03 CA CA2790653A patent/CA2790653C/en active Active
- 2011-03-03 EP EP11706253.9A patent/EP2542260B1/en active Active
- 2011-03-03 ES ES11706253.9T patent/ES2566033T3/es active Active
- 2011-03-03 RU RU2012142309/10A patent/RU2527157C2/ru active
- 2011-03-03 JP JP2012555424A patent/JP6200155B2/ja active Active
- 2011-03-03 AU AU2011222910A patent/AU2011222910B2/en active Active
- 2011-03-03 CN CN201180012606.1A patent/CN102791288B/zh active Active
- 2011-03-03 US US13/581,917 patent/US9234182B2/en active Active
-
2015
- 2015-10-08 JP JP2015200216A patent/JP6346143B2/ja active Active
-
2018
- 2018-04-04 JP JP2018072318A patent/JP2018134088A/ja active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2008102930A (ru) * | 2005-07-28 | 2009-07-27 | Пфайзер Продактс Инк. (Us) | Способы введения вакцин, новые калицивирусы кошки и варианты лечения для иммунизации животных против парвовируса кошки и вируса герпеса кошки |
| WO2008157236A1 (en) * | 2007-06-14 | 2008-12-24 | The Board Of Regents For Oklahoma State University | Vaccines containing canine parvovirus genetic variants |
Non-Patent Citations (1)
| Title |
|---|
| PARRISH C R et al, Characterization and recombination mapping of an antigenic and host range mutation of canine parvovirus, Virology, vol.148, no.1, 15.01.1986, pages 121-132. MOCHIZUKI MASAMI et al, Recombination between vaccine and field strains of canine parvovirus is revealed by isolation of virus in canine and feline cell cultures, the Journal of veterinary medical science, vol.70, no.12, December 2008, pages 1305-1314. * |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2018134088A (ja) | 2018-08-30 |
| US20120328652A1 (en) | 2012-12-27 |
| US9234182B2 (en) | 2016-01-12 |
| DK2542260T3 (en) | 2016-06-06 |
| JP2013520977A (ja) | 2013-06-10 |
| WO2011107534A1 (en) | 2011-09-09 |
| CN102791288B (zh) | 2015-02-18 |
| JP2016047053A (ja) | 2016-04-07 |
| BR112012021650A2 (pt) | 2017-02-21 |
| JP6200155B2 (ja) | 2017-09-20 |
| CA2790653C (en) | 2019-02-19 |
| EP2542260B1 (en) | 2016-03-02 |
| CN102791288A (zh) | 2012-11-21 |
| AU2011222910A1 (en) | 2012-09-27 |
| AU2011222910B2 (en) | 2014-09-18 |
| JP6346143B2 (ja) | 2018-06-20 |
| RU2012142309A (ru) | 2014-04-10 |
| ES2566033T3 (es) | 2016-04-08 |
| EP2542260A1 (en) | 2013-01-09 |
| CA2790653A1 (en) | 2011-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2542260B1 (en) | Recombinant Attenuated Parvovirus | |
| JP2022120083A (ja) | ブタサーコウイルス３型免疫原性組成物、その製造方法、およびその使用方法 | |
| DK2593136T3 (en) | LIVING, WEAKENED PARVOVIRUS | |
| EP2851428B1 (en) | Porcine torque teno virus vaccines and diagnosis | |
| JP2021516551A (ja) | Ｅｈｖ挿入部位ｕｌ４３ | |
| CN109195624B (zh) | Hev疫苗 | |
| Chang et al. | Enhanced production of Canine parvovirus VP2 protein using improved Baculovirus expression system and its immunogenicity | |
| BR112012021650B1 (pt) | Parvovírus recombinante atenuado, vacina para a proteção de animais contra infecção com parvovírus, método para a obtenção do referido parvovírus recombinante e seu uso | |
| Feng et al. | Baculovirus Expression of Feline Panleukopenia Virus Capsid Protein and Induces Robust Immune Responses in Cats |